Últimos Artículos de Lancet Diabetes & Endocrinology

- [Editorial] Diagnosing diabetes: the earlier the better
- [Comment] Who should prescribe obesity management medications? An IFSO position statement
- [Articles] Efficacy and safety of oral orforglipron in Japanese participants with obesity disease (ATTAIN-J): a double-blind, randomised, placebo-controlled, parallel-group, phase 3 trial
- [Comment] Oral small-molecule GLP-1 receptor agonist for obesity in people from Japan
- [Articles] Clinical and metabolic subtypes of recent-onset adult type 1 diabetes: a prospective cohort study
- [Correspondence] Iodine in the UK: the end of an “accidental public health triumph”
- [Corrections] Correction to Lancet Diabetes Endocrinol 2026; 14: 894–902
- [Correspondence] Bone mineral density as a surrogate endpoint in osteoporosis trials
- [Correspondence] Bone mineral density as a surrogate endpoint in osteoporosis trials – Author's reply
- [Comment] Precision medicine in type 2 diabetes: should clustering be used?
- [Correspondence] Multidisciplinary care of pituitary adenomas
- [Review] Hashimoto's thyroiditis: two decades on
- [Comment] IL-2 and immunoregulatory therapies in newly diagnosed type 1 diabetes
- [Articles] Efficacy and safety of low-dose IL-2 in people with newly diagnosed type 1 diabetes (DIABIL-2): a double-blind, multicentre, randomised, placebo-controlled, phase 2b trial
- [Review] Diabetes and the role of primary care: a global perspective
- [Editorial] Safeguarding paediatric metabolic health
- [Articles] Trends in prevalence of type 2 diabetes and intermediate hyperglycaemia in Mauritius from 1987 to 2021 based on results from the oral glucose tolerance test: a repeated cross-sectional study
- [Comment] What Mauritius teaches us about diabetes surveillance
- [Articles] Petrelintide, a human amylin analogue for the treatment of obesity (ZUPREME 1): a randomised, double-blind, placebo-controlled, phase 2 trial
- [Comment] Petrelintide and the evolving role of amylin agonism in obesity